Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2019 / Jun / Our Powers Combined
Clinical care

Our Powers Combined

Using IgM and IgA detection together can lead to better diagnosis of Zika and similar viruses

By Michael Schubert 06/17/2019 1 min read

Share

“Will Zika return? What pregnant women and others need to know about this frightening disease”

“1 in 7 babies exposed to Zika in the womb have health problems”

“A ‘perfect storm’ for the future spread of the Zika virus”

Viruses like Zika have been the subject of intense media attention, particularly since the widely publicized outbreaks in South America began. It’s well-known that fetuses and newborns who carry the virus are at risk of permanent health issues – but how can doctors conclusively identify those infected?

Felix Drexler, Head of the Virus Epidemiology Group at the Charité – Universitätsmedizin Berlin, explains that current diagnostic methods for Zika and similar viruses face one common denominator: low sensitivity. “This applies to molecular methods, because viremia is super low and super short-lived, and also antibody tests – the latter in particular in tropical areas,” he says. “People with multiple flavivirus infections mount weaker IgM responses, and these people are so full of antibodies against common flavivirus epitopes that serological test specificity diminishes greatly.”

These complications can lead to false-positive results – a dangerous situation in general, but especially so for patients in outbreak regions or those without quality health care. Women may choose to terminate a pregnancy that might otherwise be healthily carried to term – and, in cases where safe reproductive care is difficult to access, such choices can be fatal.

Why are false positives so prevalent? Partly laboratory contamination and partly low test specificity. Drexler and his colleagues experimented with using IgA as a marker for acute infection (rather than the standard IgM approach) and saw markedly increased sensitivity (1). “At least 50 percent in our study,” says Drexler. “IgM and IgA may jointly allow high sensitivity and specificity. IgG increases in paired sera add significantly to this.”

Combined antibody testing offers new diagnostic options for not only Zika, but also for other viruses, such as Middle East Respiratory Syndrome (MERS) coronavirus. If laboratory medicine professionals can distinguish between infections caused by different viruses, it helps patients and primary care providers to understand how best to proceed after diagnosis – hopefully, saving lives.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. FA Bozza et al., “Differential shedding and antibody kinetics of Zika and chikungunya viruses, Brazil”, Emerg Infect Dis, 25, 311 (2019). PMID: 30666934.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Event Tracking and Tracing with EMR
Clinical care
Event Tracking and Tracing with EMR

January 7, 2022

1 min read

Can tracking medical events, rather than patients, help us tackle diagnostic error?

2021: A Laboratory Medicine Roundup
Clinical care
2021: A Laboratory Medicine Roundup

January 18, 2022

3 min read

From transgender health care to the power of pathology podcasts, we take a look at our most popular articles of the last year

Not Just a Sample
Clinical care
Not Just a Sample

January 27, 2022

13 min read

Patient–pathologist interactions are vital – and both sides must work together to make the connection

Video: Not Just a Sample
Clinical care
Video: Not Just a Sample

January 28, 2022

1 min read

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.